WallStreetZenWallStreetZen

NASDAQ: CLDX
Celldex Therapeutics Inc Stock

$27.34+0.83 (+3.13%)
Updated Sep 27, 2023
CLDX Price
$27.34
Fair Value Price
$28.49
Market Cap
$1.29B
52 Week Low
$24.89
52 Week High
$48.40
P/E
-11.34x
P/B
4.66x
P/S
492.56x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.26M
Earnings
-$113.13M
Gross Margin
100%
Operating Margin
-3,475.7%
Profit Margin
-3,475.7%
Debt to Equity
0.08
Operating Cash Flow
-$113M
Beta
0.91
Next Earnings
Nov 7, 2023
Ex-Dividend
N/A
Next Dividend
N/A

CLDX Overview

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Zen Score

Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CLDX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CLDX ($27.34) is undervalued by 4.02% relative to our estimate of its Fair Value price of $28.49 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CLDX ($27.34) is not significantly undervalued (4.02%) relative to our estimate of its Fair Value price of $28.49 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CLDX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CLDX due diligence checks available for Premium users.

Be the first to know about important CLDX news, forecast changes, insider trades & much more!

CLDX News

Valuation

CLDX fair value

Fair Value of CLDX stock based on Discounted Cash Flow (DCF)
Price
$27.34
Fair Value
$28.49
Undervalued by
4.02%
CLDX ($27.34) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CLDX ($27.34) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CLDX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CLDX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-11.34x
Industry
13.5x
Market
13.45x

CLDX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
4.66x
Industry
5.12x
CLDX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CLDX's financial health

Profit margin

Revenue
$268.0k
Net Income
-$30.5M
Profit Margin
-11,381.3%
CLDX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CLDX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$299.3M
Liabilities
$21.8M
Debt to equity
0.08
CLDX's short-term assets ($264.82M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CLDX's short-term assets ($264.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CLDX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CLDX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$27.2M
Investing
$1.2M
Financing
$133.0k
CLDX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CLDX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CLDX$1.29B+3.13%-11.34x4.66x
CPRX$1.30B+0.25%11.06x3.46x
SAGE$1.28B+2.26%-2.15x1.30x
AMLX$1.26B-0.58%-15.71x3.26x
TGTX$1.33B+0.57%-7.00x32.92x

Celldex Therapeutics Stock FAQ

What is Celldex Therapeutics's quote symbol?

(NASDAQ: CLDX) Celldex Therapeutics trades on the NASDAQ under the ticker symbol CLDX. Celldex Therapeutics stock quotes can also be displayed as NASDAQ: CLDX.

If you're new to stock investing, here's how to buy Celldex Therapeutics stock.

What is the 52 week high and low for Celldex Therapeutics (NASDAQ: CLDX)?

(NASDAQ: CLDX) Celldex Therapeutics's 52-week high was $48.40, and its 52-week low was $24.89. It is currently -43.51% from its 52-week high and 9.84% from its 52-week low.

How much is Celldex Therapeutics stock worth today?

(NASDAQ: CLDX) Celldex Therapeutics currently has 47,260,804 outstanding shares. With Celldex Therapeutics stock trading at $27.34 per share, the total value of Celldex Therapeutics stock (market capitalization) is $1.29B.

Celldex Therapeutics stock was originally listed at a price of $439.20 in Dec 31, 1997. If you had invested in Celldex Therapeutics stock at $439.20, your return over the last 25 years would have been -93.78%, for an annualized return of -10.51% (not including any dividends or dividend reinvestments).

How much is Celldex Therapeutics's stock price per share?

(NASDAQ: CLDX) Celldex Therapeutics stock price per share is $27.34 today (as of Sep 27, 2023).

What is Celldex Therapeutics's Market Cap?

(NASDAQ: CLDX) Celldex Therapeutics's market cap is $1.29B, as of Sep 28, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Celldex Therapeutics's market cap is calculated by multiplying CLDX's current stock price of $27.34 by CLDX's total outstanding shares of 47,260,804.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.